Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
The FDA agreed to review Moderna’s experimental mRNA influenza vaccine after Moderna resubmitted its application with modifications.
Foreign substances such as mold, hair, and silicon dioxide (silica) were found in COVID-19 vaccines, potentially introduced ...
The global vaccine Contract Development and Manufacturing Organization (CDMO) market is projected to expand at a compound ...
Union Health Minister J P Nadda launched the indigenously manufactured tetanus and adult diphtheria vaccine in Kasauli. The ...
Union Health Minister JP Nadda on Saturday launched the indigenously manufactured Tetanus and Adult Diphtheria (Td) vaccine ...
In a sudden reversal, the US Food and Drug Administration has agreed to review Moderna’s experimental mRNA influenza vaccine.
Researchers suggest a vaccine could replace multiple jabs every year for seasonal respiratory infections and be on hand in the event of a new pandemic.
They're continuing their work with the World Health Organization.